Switching Akt: From survival signaling to deadly response

BioEssays

Volumn 31, Issue 5, 2009, Pages 492-495

  Los, Marek ^a,b   Maddika, Subbareddy ^c   Erb, Bettina ^a   Schulze Osthoff, Klaus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BioApplications Enterprises Winnipeg   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Apoptosis; Oncogenes; Oxidative stress; Senescence

Indexed keywords

ANTIOXIDANT; ETOPOSIDE; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; REACTIVE OXYGEN METABOLITE;

AEROBIC METABOLISM; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL AGING; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW;

ANIMALS; CELL AGING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 66449118214     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200900005     Document Type: Article

References (25)

1. Nogueira, V., Park, Y., Chen, C. C., Xu, P. Z., Chen, M. L., et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008. 14: 458-470.
2. Vivanco, I. and Sawyers, C. L., The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002. 2: 489-501.
3. Yuan, T. L. and Cantley, L. C., PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008. 27: 5497-5510.
4. Hay, N., The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005. 8: 179-183.
5. Manning, B. D. and Cantley, L. C., AKT/PKB signaling: navigating downstream. Cell 2007. 129: 1261-1274.
6. Plas, D. R. and Thompson, C. B., Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005. 24: 7435-7442.
7. Pelengaris, S., Khan, M. and Evan, G., C-MYC: more than just a matter of life and death. Nat Rev Cancer 2002. 2: 764-776.
8. Hipfner, D. R. and Cohen, S. M., Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol 2004. 5: 805-815.
9. Tanaka, H., Matsumura, I., Ezoe, S., Satoh, Y., Sakamaki, T., et al. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 2002. 9: 1017-1029.
10. Kopnin, P. B., Agapova, L. S., Kopnin, B. P. and Chumakov, P. M., Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res 2007. 67: 4671-4678.
11. Los, M., Stroh, C., Jänicke, R. U., Engels, I. H. and Schulze-Osthoff, K., Caspases: more than just killers? Trends Immunol 2001. 22: 31-34.
12. Galluzzi, L., Joza, N., Tasdemir, E., Maiuri, M. C., Hengartner, M., et al. No death without life: vital functions of apoptotic effectors. Cell Death Differ 2008. 15: 1113-1123.
13. Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006. 10: 241-252.
14. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997. 16: 6151-6161.
15. Liou, J. S., Chen, C. Y., Chen, J. S. and Faller, D. V., Oncogenic ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species. J Biol Chem 2000. 275: 39001-39011.
16. Maddika, S., Ande, S. R., Wiechec, E., Hansen, L. L., Wesselborg, S., et al. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J Cell Sci 2008. 121: 979-988.
17. Maddika, S., Panigrahi, S., Wiechec, E., Wesselborg, S., Fischer, U., et al. Unscheduled Akt-triggered activation of CDK2 as a key effector mechanism of apoptin's anticancer toxicity. Mol Cell Biol 2009. 29: 1235-1248.
18. Trotman, L. C., Alimonti, A., Scaglioni, P. P., Koutcher, J. A., Cordon- Cardo, C., et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006. 441: 523-527.
19. Ahn, J. Y., Liu, X., Liu, Z., Pereira, L., Cheng, D., et al. Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J 2006. 25: 2083-2095.
20. Campisi, J., Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005. 120: 513-522.
21. Jänicke, R. U., Sohn, D., Essmann, F. and Schulze-Osthoff, K., The multiple battles fought by anti-apoptotic p21. Cell Cycle 2007. 6: 407-413.
22. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H. K., Dotan, Z. A., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005. 436: 725-730.
23. Héron-Milhavet, L., Franckhauser, C., Rana, V., Berthenet, C., Fisher, D., et al. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 2006. 26: 8267-8280.
24. Garcia-Echeverria, C. and Sellers, W. R., Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008. 27: 5511-5526.
25. Jänicke, R. U., Sohn, D. and Schulze-Osthoff, K., The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008. 15: 959-976.